The discordant incidence and mortality reflect prostate cancer’s indolent growth and low fatality especially when diagnosed without metastasis [3, 4], and potential overdiagnosis of clinically insignificant cancer partly contributed by the limitations of prostate-specific antigen (PSA) testing [5, 6]. This evidence concerns the gene KLK3 and prostate carcinoma.